Patients with newly or active diffuse Systemic sclerosis (SSc) at the time of screening MedDRA version: 21.0 Level: LLT Classification code 10012977 Term: Diffuse systemic sclerosis System Organ Class: 100000004859
Conditions
Interventions
Product Name: Itacitinib
Product Code: INCB039110
Pharmaceutical Form: Tablet
INN or Proposed INN: ITACITINIB
Current Sponsor code: INCB039110
Concentration unit: mg milligram(s)
Concentration type: e
Sponsors
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Adult patient (>/= 18 years old), - Patient with a diagnosis of diffuse SSc, as defined by the American College of Rheumatology / EULAR 2013 criteria, - Patient with a SSc disease duration of less than 36 months (defined as time from first non-Raynaud phenomenon manifestation) or with an active SSc disease, as defined by EUSTAR disease activity score, - Patient with a modified Rodnan skin score (mRSS) > /= 10 and =65 years) yes F.1.3.1 Number of subjects for this age range 4
Exclusion criteria
Exclusion criteria: - Previous treatment with itacitinib or a Janus kinase (JAK) inhibitor, - Contra-indications to itacitinib or Janus kinase inhibitor, - Failure to sign the informed consent or unable to consent - Patient participating in another investigational therapeutic study, - Current, or history of recurrent infections, including HBV, HCV, HIV - Patient with other uncontrolled diseases, including drug or alcohol abuse, severe psychiatric diseases, that could interfere with participation in the trial according to the protocol, - Patient suspected not to be observant to the proposed treatments, - Patient who have white blood cell count = 4,000/mm3, - Patient who have platelet count = 100,000/mm3, - Patients who have ALT or AST level greater that 3 times the upper limit of normal - Patient who have triglyceride level greater than 5g/L - Pregnant or breastfeeding woman. - Patient receiving or having received mycophenolate mofetil or methotrexate within the last month (possible inclusion beyond one month), - Patient receiving or having received cyclophosphamide or rituximab within the last three months (possible inclusion beyond 3 months), - Patient receiving or having received a biotherapy (anti-TNF, abatacept or tocilizumab) in the last 3 months (possible inclusion beyond 3 months).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Timepoint(s) of evaluation of this end point: Day 360;Main Objective: The main objective of this study is to show a decrease of skin fibrosis, as evaluated by the modified Rodnan skin score, after 360 days of treatment, in patients with diffuse SSc treated with itacitinib when compared to patients treated with a placebo;Secondary Objective: - to evaluate the safety of itacitinib in patients with SSc - to compare the efficacy of itacitinib versus placebo in terms of disease activity, quality of life and disability ;Primary end point(s): The primary outcome is the change in modified Rodnan skin score at 360 days. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Security profile: - Proportion of patients deceased at 360 days - Adverse events at 180 and 360 days - Severe adverse events at 180 and 360 days. SSc disease activity - Change in modified Rodnan skin score at 90, 180, 270 days - Proportion of patients with an improved modified Rodnan skin score at 90, 180, 270, 360 days - Proportion of patients with an active disease according to the EUSTAR SSc activity score at 180 and 360 days. - Change in the Combined Response Index in Diffuse Systemic Sclerosis (CRISS) score - Physicians and patients visual analogue scales Quality of life and disability - SF-36 and EQ5D scales - HAQ-DI scale ;Timepoint(s) of evaluation of this end point: at 90, 180, 270, 360 days | — |
Countries
France
Contacts
Public ContactDRCI Hôpital St Louis
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Outcome results
None listed